References
- Segawa C, Wada T, Furuichi K, Takasawa K, Yokoyama H, Kobayashi K. Steroid pulse therapy in lupus cystitis. Intern Med 1996;35:155–8.
- Narvaez J, Perez-Vega C, Castro-Bohorquez FJ, Garcia-Quintana AM, Biosca M, Vilaseca-Momplet J. Intestinal pseudo-obstruction in systemic lupus erythematosus. Scand J Rheumatol 2003;32:191–5.
- Min JK, Byun JY, Lee SH, Hong YS, Park SH, Cho CS, et al. Urinary bladder involvement in patients with systemic lupus erythematosus: with review of the literature. Korean J Intern Med 2000;15:42–50.
- Moriuchi J, Ichikawa Y, Takaya M, Shimizu H, Tokunaga M, Eguchi T, et al. Lupus cystitis and perforation of the small bowel in a patient with systemic lupus erythematosus and overlapping syndrome. Clin Exp Rheumatol 1989;7:533–6.
- Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997;56:690–2.
- Hoshi K, Matsuda M, Ishikawa M, Mitsuhashi S, Gono T, Hashimoto T, et al. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin Rheumatol 2004;23:252–5.
- Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an openlabeled pilot study. Kidney Int 2005;68:813–7.
- Kunz J, Hall MN. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression Trends Biochem Sci 1993;18: 334–8.
- Almawi WY, Melemedjian OK. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant 2000;15:1916–8.
- Mori A, Suko M, Kaminuma O, Inoue S, Ohmura T, Hoshino A, et al. IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. J Immunol 1997 15;158: 3659–65.